NantKwest Inc. (NASDAQ:NK) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $20.00.

A number of research analysts recently commented on NK shares. Zacks Investment Research downgraded shares of NantKwest from a “hold” rating to a “sell” rating in a research report on Tuesday, September 20th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $23.00 target price (down from $32.00) on shares of NantKwest in a research report on Wednesday, August 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $18.00 target price on shares of NantKwest in a research report on Friday, August 19th.

In other NantKwest news, insider Barry J. Simon sold 32,000 shares of the firm’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $7.49, for a total transaction of $239,680.00. Following the transaction, the insider now directly owns 3,334,906 shares of the company’s stock, valued at approximately $24,978,445.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 73.06% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. boosted its stake in NantKwest by 100.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 39,753 shares of the company’s stock valued at $248,000 after buying an additional 19,878 shares during the period. A.R.T. Advisors LLC purchased a new stake in NantKwest during the second quarter valued at approximately $205,000. State Street Corp boosted its stake in NantKwest by 8.5% in the second quarter. State Street Corp now owns 135,270 shares of the company’s stock valued at $843,000 after buying an additional 10,640 shares during the period. ProShare Advisors LLC boosted its stake in NantKwest by 3.5% in the second quarter. ProShare Advisors LLC now owns 63,063 shares of the company’s stock valued at $392,000 after buying an additional 2,137 shares during the period. Finally, Vident Investment Advisory LLC boosted its stake in NantKwest by 13.3% in the second quarter. Vident Investment Advisory LLC now owns 102,500 shares of the company’s stock valued at $638,000 after buying an additional 12,056 shares during the period. Institutional investors own 24.13% of the company’s stock.

NantKwest (NASDAQ:NK) opened at 7.32 on Friday. NantKwest has a 12 month low of $5.43 and a 12 month high of $19.43. The firm has a 50 day moving average of $8.06 and a 200-day moving average of $7.65. The firm’s market cap is $602.52 million.

NantKwest Company Profile

NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.

5 Day Chart for NASDAQ:NK

Receive News & Stock Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related stocks with our FREE daily email newsletter.